Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells

Cancer Research

Volumn 73, Issue 14, 2013, Pages 4451-4460

  Zhu, Guangyu ^a,b   Song, Lina ^a   Lippard, Stephen J ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; OCTAMER TRANSCRIPTION FACTOR; PLASMID VECTOR;

ANIMAL CELL; ARTICLE; CELL MOTILITY; CONTROLLED STUDY; DNA CROSS LINKING; DNA HISTONE INTERACTION; DRUG DELIVERY SYSTEM; DRUG DNA BINDING; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; EXCISION REPAIR; EXPRESSION VECTOR; IN VITRO STUDY; MAMMAL CELL; NONHUMAN; NUCLEOSOME; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; CISPLATIN; DINUCLEOSIDE PHOSPHATES; DNA ADDUCTS; DNA MISMATCH REPAIR; DNA REPAIR; DNA REPLICATION; HELA CELLS; HUMANS; NUCLEOSOMES; TRANSCRIPTION, GENETIC;

EID: 84880866225     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0198     Document Type: Article

References (50)

1. Rosenberg B, Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969;222: 385-6.
2. Einhorn LH, Williams SD. The role of cis-platinum in solid-tumor therapy. N Engl J Med 1979;300:289-91.
3. Smith IE, Talbot DC. Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br J Cancer 1992;65:787-93.
4. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev 2007;107:1387-407.
5. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84.
7. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-98.
8. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999;98:285-94.
9. Lippard SJ, Hoeschele JD. Binding of cis- and trans- dichlorodiammineplatinum( II) to the nucleosome core. Proc Natl Acad Sci USA 1979; 76:6091-5.
10. Danford AJ, Wang D, Wang Q, Tullius TD, Lippard SJ. Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl Acad Sci USA 2005;102:12311-6.
11. Ober M, Lippard SJ. Cisplatin damage overrides the predefined rotational setting of positioned nucleosomes. J Am Chem Soc 2007;129: 6278-86.
12. Ober M, Lippard SJ. A 1, 2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes. J Am Chem Soc 2008;130:2851-61.
13. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995;270: 1842-5.
14. Zhu G, Lippard SJ. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry 2009;48:4916-25.
15. Räschle M, Knipscheer P, Enoiu M, Angelov T, Sun J, Griffith JD, et al. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 2008;134:969-80.
16. Knipscheer P, Räschle M, Smogorzewska A, Enoiu M, Ho TV, Schärer OD, et al. The Fanconi anemia pathway promotes replication- dependent DNA interstrand cross-link repair. Science 2009;326:1698-701.
17. Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker R, Howell SB, et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992; 12:3689-98.
18. Millard JT, Wilkes EE. cis- and trans-Diamminedichloroplatinum(II) interstrand cross-linking of a defined sequence nucleosomal core particle. Biochemistry 2000;39:16046-55.
19. Millard JT, Spencer RJ, Hopkins PB. Effect of nucleosome structure on DNA interstrand cross-linking reactions. Biochemistry 1998;37: 5211-9.
20. Gottesfeld JM, Belitsky JM, Melander C, Dervan PB, Luger K. Blocking transcription through a nucleosome with synthetic DNA ligands. J Mol Biol 2002;321:249-63.
21. Suto RK, Edayathumangalam RS, White CL, Melander C, Gottesfeld JM, Dervan PB, et al. Crystal structures of nucleosome core particles in complex with minor groove DNA-binding ligands. J Mol Biol 2003; 326:371-80.
22. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009;1:280-91.
23. Ang WH, Brown WW, Lippard SJ. Preparation of mammalian expression vectors incorporating site-specifically platinated-DNA lesions. Bioconjug Chem 2009;20:1058-63.
24. Ang WH, Myint M, Lippard SJ. Transcription inhibition by platinum- DNA cross-links in live mammalian cells. J Am Chem Soc 2010;132: 7429-35.
25. Zhu G, Myint M, Ang WH, Song L, Lippard SJ. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells. Cancer Res 2012;72:790-800.
26. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011;11:467-80.
27. Corda Y, Job C, Anin M-F, Leng M, Job D. Spectrum of DNA-platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases. Biochemistry 1993;32:8582-8.
28. Zhu G, Chang P, Lippard SJ. Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. Biochemistry 2010;49:6177-83.
29. Workman JL. Nucleosome displacement in transcription. Genes Dev 2006;20:2009-17.
30. Luger K. Dynamic nucleosomes. Chromosome Res 2006;14:5-16.
31. Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 2006;7: 437-47.
32. Mymryk JS, Zaniewski E, Archer TK. Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. Proc Natl Acad Sci USA 1995;92:2076-80.
33. Wu B, Davey CA. Platinum drug adduct formation in the nucleosome core alters nucleosome mobility but not positioning. Chem Biol 2008; 15:1023-8.
34. Todd RC, Lippard SJ. Consequences of cisplatin binding on nucleosome structure and dynamics. Chem Biol 2010;17: 1334-43.
35. Paquet F, Perez C, Leng M, Lancelot G, Malinge J-M. NMR solution structure of a DNA decamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum(II). J Biomol Struct Dyn 1996;14:67-77.
36. Coste F, Malinge J-M, Serre L, Shepard W, Roth M, Leng M, et al. Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 Å resolution: hydration at the platinated site. Nucleic Acids Res 1999;27:1837-46.
37. Wang D, Hara R, Singh G, Sancar A, Lippard SJ. Nucleotide excision repair from site-specifically platinum-modified nucleosomes. Biochemistry 2003;42:6747-53.
38. Zhang N, Lu X, Legerski RJ. Partial reconstitution of human interstrand cross-link repair in vitro: characterization of the roles of RPA and PCNA. Biochem Biophys Res Commun 2003;309:71-8.
39. Noll DM, Mason TM, Miller PS. Formation and repair of interstrand cross-links in DNA. Chem Rev 2006;106:277-301.
40. Muniandy PA, Liu J, Majumdar A, Liu S-T, Seidman MM. DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 2010;45:23-49.
41. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20: 7980-90.
42. Thompson LH. Evidence that mammalian cells possess homologous recombinational repair pathways. Mutat Res 1996;363:77-88.
43. Bessho T, Mu D, Sancar A. Initiation of DNA interstrand cross-link repair in humans: the nucleotide excision repair system makes dual incisions 50 to the cross-linked base and removes a 22- to 28-nucleotide- long damage-free strand. Mol Cell Biol 1997;17:6822-30.
44. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90.
45. Enoiu M, Jiricny J, Schärer OD. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic Acids Res 2012;40:8953-64.
46. Topping RP, Wilkinson JC, Scarpinato KD. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J Biol Chem 2009;284:14029-39.
47. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
48. Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 2006;5:1239-47.
49. Wu Q, Christensen LA, Legerski RJ, Vasquez KM. Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep 2005;6:551-7.
50. Liu T, Ghosal G, Yuan J, Chen J, Huang J. FAN1 acts with FANCIFANCD2 to promote DNA interstrand cross-link repair. Science 2010;329:693-6.